<DOC>
	<DOC>NCT02449616</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.</brief_summary>
	<brief_title>Evaluation of Repeat Administration of Purified Poloxamer 188</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>Completed participation in study MST18801 (EPIC study) Subject age 4 through 65 years Subject is experiencing acute pain typical of VOC and requires treatment with parenteral opioid analgesia Subject requires hospitalization Subject has acute chest syndrome Subject's laboratory results indicate inadequate organ function Subject is pregnant or nursing an infant Subject had a painful crisis requiring hospitalization within the preceding 14 days Subject has been transfused within the past 14 days Subject has complications related to SCD</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sickle cell</keyword>
	<keyword>vaso-occlusive crisis</keyword>
</DOC>